Challenges and innovations in primary sclerosing cholangitis clinical trials: Evaluating HK-660S and the path forward: Editorial on "Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial".
作者信息
Nishad Nilanga
机构信息
Department of Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
出版信息
Clin Mol Hepatol. 2025 Apr;31(2):581-583. doi: 10.3350/cmh.2024.0942. Epub 2024 Nov 4.
Abstract
摘要
相似文献
1
Challenges and innovations in primary sclerosing cholangitis clinical trials: Evaluating HK-660S and the path forward: Editorial on "Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial".原发性硬化性胆管炎临床试验中的挑战与创新：评估HK-660S及未来方向：关于“HK-660S治疗原发性硬化性胆管炎患者的安全性和有效性：一项随机双盲2a期试验”的社论
Clin Mol Hepatol. 2025 Apr;31(2):581-583. doi: 10.3350/cmh.2024.0942. Epub 2024 Nov 4.
2
Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial.HK-660S治疗原发性硬化性胆管炎患者的安全性和有效性：一项随机双盲2a期试验。
Clin Mol Hepatol. 2025 Jan;31(1):119-130. doi: 10.3350/cmh.2024.0629. Epub 2024 Sep 24.
3
A novel clinical trial for primary sclerosing cholangitis from Asia: All regional endeavors should improve global management of primary sclerosing cholangitis: Editorial on "Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial".一项来自亚洲的原发性硬化性胆管炎新型临床试验：所有地区的努力均应改善原发性硬化性胆管炎的全球管理：关于“HK - 660S治疗原发性硬化性胆管炎患者的安全性和有效性：一项随机双盲2a期试验”的社论
Clin Mol Hepatol. 2025 Apr;31(2):584-588. doi: 10.3350/cmh.2024.0945. Epub 2024 Nov 6.
4
Correspondence to editorial on "Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial".致关于“HK-660S治疗原发性硬化性胆管炎患者的安全性和有效性：一项随机双盲2a期试验”的社论的信函。
Clin Mol Hepatol. 2025 Apr;31(2):e158-e160. doi: 10.3350/cmh.2024.0989. Epub 2024 Nov 11.
5
Critical Considerations in Evaluating the Therapeutic Potential of HK-660S for Primary Sclerosing Cholangitis.
Clin Mol Hepatol. 2025 Mar 17. doi: 10.3350/cmh.2025.0239.
6
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis.PRIMIS：一项关键性、随机、3 期研究的设计，评估非甾体法尼醇 X 受体激动剂西罗福西安在非肝硬化原发性硬化性胆管炎患者中的安全性和疗效。
BMC Gastroenterol. 2023 Mar 15;23(1):75. doi: 10.1186/s12876-023-02653-2.
7
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.熊去氧胆酸可改善原发性硬化性胆管炎的胆汁淤积。
J Hepatol. 2017 Sep;67(3):549-558. doi: 10.1016/j.jhep.2017.05.009. Epub 2017 May 18.
8
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.NGM282，一种 FGF19 类似物，在原发性硬化性胆管炎中的作用：一项多中心、随机、双盲、安慰剂对照的 II 期临床试验。
J Hepatol. 2019 Mar;70(3):483-493. doi: 10.1016/j.jhep.2018.10.035. Epub 2018 Nov 9.
9
FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial.原发性硬化性胆管炎粪便微生物群移植（FARGO）：一项随机、多中心、IIa期、安慰剂对照试验的研究方案
BMJ Open. 2025 Jan 6;15(1):e095392. doi: 10.1136/bmjopen-2024-095392.
10
Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis.探索肝脏领域：原发性硬化性胆管炎的新型药物治疗方法。
Expert Opin Pharmacother. 2024 May;25(7):895-906. doi: 10.1080/14656566.2024.2362263. Epub 2024 May 31.
引用本文的文献
1
Correspondence to editorial on "Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial".致关于“HK-660S治疗原发性硬化性胆管炎患者的安全性和有效性：一项随机双盲2a期试验”的社论的信函。
Clin Mol Hepatol. 2025 Apr;31(2):e158-e160. doi: 10.3350/cmh.2024.0989. Epub 2024 Nov 11.
本文引用的文献
1
Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial.HK-660S治疗原发性硬化性胆管炎患者的安全性和有效性：一项随机双盲2a期试验。
Clin Mol Hepatol. 2025 Jan;31(1):119-130. doi: 10.3350/cmh.2024.0629. Epub 2024 Sep 24.
2
Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: A systematic review and meta-analysis.生物制剂在炎症性肠病相关原发性硬化性胆管炎中的疗效和安全性：系统评价和荟萃分析。
Hepatol Commun. 2024 Jan 11;8(1). doi: 10.1097/HC9.0000000000000347. eCollection 2024 Jan 1.
3
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma.美国肝病研究学会关于原发性硬化性胆管炎和胆管癌的实践指南。
Hepatology. 2023 Feb 1;77(2):659-702. doi: 10.1002/hep.32771. Epub 2022 Oct 20.
4
Small duct primary sclerosing cholangitis: A discrete variant or a bridge to large duct disease, a practical review.小胆管原发性硬化性胆管炎：一种独立的变异型还是通向大胆管疾病的桥梁，一项实用性综述
World J Hepatol. 2022 Mar 27;14(3):495-503. doi: 10.4254/wjh.v14.i3.495.
5
Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease.无炎症性肠病的小胆管原发性硬化性胆管炎在基因上与大胆管疾病不同。
Liver Int. 2014 Nov;34(10):1488-95. doi: 10.1111/liv.12492. Epub 2014 Mar 7.
6
THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION?环境与疾病：关联还是因果关系？
Proc R Soc Med. 1965 May;58(5):295-300. doi: 10.1177/003591576505800503.
Zotero 插件